SCHEMBL2931805

SCHEMBL2931805

Fc1ccc(-c2nc3[nH]ncc3c(-c3ccc(F)cc3)c2-c2ccnc(Cl)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.47
MAPK11 Q15759 5/20 0.47
CSNK1D P48730 1/20 0.47
MAPK13 O15264 4/20 0.43
MAPK12 P53778 4/20 0.43
ADORA2A P29274 1/20 0.40
ADORA2B P29275 1/20 0.40
ADORA1 P30542 1/20 0.40
METAP2 P50579 1/20 0.37
TNIK Q9UKE5 1/20 0.37
IDO1 P14902 1/20 0.36
KIT P10721 2/20 0.36
RPS6KB1 P23443 1/20 0.35
NUDT1 P36639 1/20 0.35
HTR2C P28335 1/20 0.34
TGFBR1 P36897 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1384646 0.84 MAPK14 (0.40) MAPK14MAPK11CSNK1DMAPK13MAPK12
SCHEMBL2931861 0.84 MAPK14 (0.48) MAPK14MAPK11CSNK1DMAPK13MAPK12
SCHEMBL29652689 0.84 MAPK14 (0.48) MAPK14MAPK11CSNK1DMAPK13MAPK12
SCHEMBL1384542 0.80 MAPK14 (0.46) MAPK14MAPK11CSNK1DMAPK13MAPK12
SCHEMBL1386446 0.79 MAPK14 (0.49) MAPK14MAPK11CSNK1DMAPK13MAPK12
SCHEMBL1386787 0.78 HSD17B1 (0.44) MAPK14MAPK11CSNK1DMAPK13MAPK12
SCHEMBL2926060 0.76 MAPK14 (0.46) MAPK14MAPK11CSNK1DMAPK13MAPK12
SCHEMBL1385415 0.75 MAPK14 (0.45) MAPK14MAPK11CSNK1DMAPK13MAPK12
SCHEMBL1386972 0.75 MAPK1 (0.41) MAPK14MAPK11MAPK13MAPK12ADORA2A
SCHEMBL1384718 0.74 MAPK14 (0.47) MAPK14MAPK11CSNK1DMAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885MAPK11 40/4885CSNK1D 75/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MAPK11 40/4885CSNK1D 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.